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Abstract
Circular RNAs (circRNAs) are a class of long non-coding RNAs (lncRNAs) which have a circular and closed loop structure.
They are ubiquitous, stable, conserved and diverse RNA molecules with a range of activities such as translation and
splicing regulation, which are able to interacting with RNA-binding proteins and specially miRNA sponge. The expression
patterns of the circRNAs exhibited tissue specificity and also, step and stage specificity. Accumulating evidences
approved the critical role of circular RNAs in many cancers such as ovarian cancer. Given that these molecules exert their
effects through multiple cellular and molecular mechanisms (i.e., angiogenesis, apoptosis, growth, and metastasis) which
are involved in cancer pathogenesis, circular RNAs, in particular, act by controlling cell proliferation in ovarian cancer, so
that, it has been shown that the deregulation of these molecules is associated with initiation and progression of ovarian
cancer. Therefore, they are attractive molecules which have introduced them as cancer biomarkers. Moreover, they could
be used as new therapeutic candidates for developing novel treatment strategies. Here, for first time, we have provided
a comprehensive review on the recent knowledge of circular RNAs and their pathological roles in the ovarian cancer.
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Introduction
The majority portion of genome (approximately 98%)
is assigned to non-coding RNAs (ncRNAs) rather
than protein coding mRNAs [1]. They are catego-
rized into two main group: (1) housekeeper ncRNAs,
which are consist of tRNAs, rRNAs, snoRNAs and
snRNAs; (2) regulatory ncRNAs. Based on the nu-
cleotide fragment length, the regulatory ncRNAs can
be classified into < 200 nucleotides in transcript
length, some of which are microRNAs (miRNAs) and
siRNAs, and the long non coding RNAs (lncRNAs)
which possess transcripts with more than 200 nucle-
otides in length [2, 3].
Circular RNAs (circRNAs) group is a member of
lncRNAs with a large variation in length ranged from hun-
dreds to thousands nucleotides [4]. During the pre-mRNA
splicing, the 5′ end of upstream exon and the 3′ end of a
downstream exon or the ends of an individual exon could
join together to generate a circRNAs. The Circular essence
of circRNAs make them more stable against RNase in com-
parison with linear RNA forms [5]. While majority of cir-
cRNAs are originated from coding pre-mRNA, but they are
classified as lncRNAs. The circRNAs was firstly discovered
in 1979 [6], but the technical limitation hindered the wide
identifications and investigations. Until last two decade,
emerging rapid advanced in molecular techniques like next
generation sequencing, the number of identified circRNAs
and researches on their function [7, 8].
Like other lncRNAs, circRNAs could be implicated in
RNA or protein sponging to modulate gene expression.
The most well-known mechanisms is in miRNA regula-
tion by acting as competing endogenous miRNA sponge
elements; in this way they post-transcriptionally pro-
vided mRNA escape miRNA repression [9, 10]. Besides,
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they are involved in cell cycle and other physiological
cell processes by making complexes with proteins [11].
In recent years, they are attracting considerable research
attribute to their roles in initiation and progression of
human malignancies, especially cancers.
Ovarian cancer is one of the most common gyneco-
logic disease worldwide. In 2018, more than 295,000
new cases were diagnosed and approximately 184,000
deaths were reported worldwide [12]. Despite develops
in chemotherapy and surgical treatment, the survival
rate is not favorable, because of poor prognosis and
cancer recurrence [13]. Without doubt, clearing the cir-
cRNAs function and roles will improve knowledge of
ovarian cancer and provide new chances and opportun-
ities to develop more effective treatment or diagnostic
approaches. Herein, we reviewed properties and function
of circRNAs in cancers. We also highlight the circRNAs
dysregulation and functions in the regulation of ovarian
cancers.
CircRNA biogenesis
In eukaryotic genes, non-coding introns that are between
exons are removed after transcription by alternative splicing
of pre-mRNA transcript. (in alternative splicing process of
eukaryotic pre-mRNA, the introns that are non-coding re-
gion located between exons are removed after transcrip-
tion.) [14]. After that, exons are reattached to each other
and the spliced out introns can be formed linear or lariat
molecules. Many evidence have demonstrated that circular
RNAs are originated during splicing pre-mRNAs. like
mRNAs, circRNAs are transcribed by RNA polymerase II
(Pol II) but they have not terminal structure such as 3′
poly-A tail and 5′ Cap that exist in the fate of RNA tran-
scripts [4]. The lack of free end in circRNAs lead to be re-
sistant toward endonuclease and subsequently, are more
stable than their linear counterpart.
Based on sequences and genomic origins, circRNAs
are divided into three classes: intronic, exon-intron and
exonic, which is the most prevalent form of circRNAs
(Fig. 1) [15]. Exonic circRNAs are formed during back-
splicing or Exon skipping and are usually catalyzed by
the spliceosomal machinery [16]. In back-splicing, which
also called circle splicing or head-to-tail splicing, the
segments of spliceosome lead to attach the downstream
splice donor (5′ end of the intron) to an upstream splice
acceptor (3′end of the intron) and circular inverting
Fig. 1 The kind of biogenesis of circRNAs: (a) Standard splicing (conventional linear splicing); (b) circRNAs is generated by a process called, Backsplicing:
this splicing lead to creating 1) exonic circRNA that can make two forms including single exon circRNA and multiple exon circRNA, 2) Exonic-Intronic
circRNA and 3) Intronic circRNA
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RNA are produced by covalently linked ends. In multiple
exons, a downstream end of exon splices to the initiation
site of an upstream exon. It may also happen with single
exon; in this case, the 3′end of one exon binds to the5′
end site [17, 18].
Exon skipping is the other model of splicing for producing
of exonic circRNAs. In this process, when one or maybe
more of the exons skipped, the introns with a loop structure,
known as lariat (which resembles lasso), can formed exon-
containing lariat during internal splicing [19–21].
Generally, in eukaryotic genes, introns undergoing
standard splicing is separated and degraded by enzymes.
However, some of the introns have conservative se-
quences at both ends of them. These motifs are GU-rich
element (7-nucleotide) located at the near 5′ splice site
and the C-rich element (11-nucleotide) at 3′-branch site.
Due to preserve motifs, The lariat introns escape of deb-
ranching enzymes, consequently, RNAs can be circular-
ized and circular intronic RNAs (ciRNAs) are produced
[18, 22]. A feature of the intronic circRNAs that distin-
guishes them from exonic circRNAs is single unique 2′–
5′ linkage, while in exonic circRNAs the phospholipid
linkage is 3′-5′. CircRNAs are settled in the nucleus and
have a role in the regulation of parent genes [23].
Finally, exon-intron circular RNAs (EIciRNAs) can be
produced from circularized exons with intron preserved
between exons (Fig. 1). According further studies, it is
confirmed that circRNAs and EIciRNAs are involved in
Pol II transcription and both of them play role in regula-
tion of parental gene expression. Like ciRNAs, EIciRNAs
are located in nucleus [17, 24].
Recently, it is shown that some classes of the enzyme
are effective in circRNAs biogenesis. RNA binding pro-
teins (RBPs) is a group of enzymes that have a role in the
generation of circRNAs in some situations and is demon-
strated to act as a regulator in activation or repression cir-
cRNAs. Actually, it is proven that they play a crucial role
in the control of RNA such as splicing [25]. Ashwal-Fluss
et al. are exposed in their research that RBPs can monitor
muscle-blind protein (MBL) levels in the fly brain [26]. In
this process, when MBL level is too high, RBPs attach to
pre-mRNAs and prevent to convert linear RNA and cause
circRNAs, afterward, translation stops and MBL protein
has not produced [27]. ADAR (adenosine deaminases act-
ing on RNA) is another enzyme that involved in circRNAs
biogenesis and can regulate RBPs level. Since ADAR has
the function in RNA editing, is imperative for mammalian
development. In kinds of research, it is expressed that
ADAR causes decreasing formation of circRNAs through
debilitating and editing RNA duplexes [7, 28].
Circular RNAs and their roles in cancer pathogenesis
Cancer is one of very important health problems [29, 30].
It has been showed that a variety of internal (genetics and
epigenetic factors) and external factors involved in cancer
pathogenesis [29, 31]. Among epigenetic factors, non-
coding RNAs have critical roles in the pathogenesis of
many diseases such as cancer, cardiovascular diseases, and
diabetes [32–35]. Considering the many challenges associ-
ated the effects of non-coding RNAs such as lncRNAs and
miRNAs and their role in cancer, nowadays a new cat-
egory of these non-coding RNAs, called circRNAs, have
attracted considerable attention. Many evidence in recent
years have confirmed that circRNAs play an important
role in the onset and progression of various cancers in-
cluding gastric cancer, esophageal cancer, ovarian cancer,
bladder cancer, renal carcinoma, oral carcinoma, lung
cancer, and hepatic carcinoma (Table 1) [42, 63–66]. Ac-
cording to development of techniques that were able to
discover function of circRNAs, it is proven that they can
affect on several pathways and aberrant expression of
them causes various disease including cancer. Recently, it
is demonstrated that circRNAs in numerous cancers
changes expression level or even can interact with micro-
RNAs and act as sponge miRNAs.
During a study, the expression of circ-104,916 was inves-
tigated in gastric cancer (GC) by microarray. In this inquiry,
circ-104,916 was downregulated in tissue GC compare with
normal tissue. After that, they performed quantitative real-
time PCR (in 70 pairs of human GC specimens) to confirm
the results of the microarray and figured out that the results
were matched. They also showed that the overexpression of
circ-104,916 via pcDNA-circ-104,916 in two GC cell line
(BGC823, MGC803) lead to significantly suppressed prolif-
eration, invasion, and migration via changing the epithelial-
mesenchymal transition (EMT) manner. According to the
results, they claim that circ-104,916 would be appropriate
biomarker for GC [36]. Recently, a novel circRNAs named
Cdr1, antisense to the cerebellar degeneration-related pro-
tein 1 transcript, has been discovered. This circRNAs also
called ciRS-7 which was because of the appearance as a
powerful sponge for miR-7 [67, 68]. Since the result of
qRT-PCR in a research demonstrated that ciRS-7 was over-
expressed in GC samples compared with control tissues, it
was suggested that this circRNAs could serve as a potential
biomarker in GC. On the other hand, in this study the cor-
relation between miR-7 and ciRS-7 was checked out. It was
observed that the expression level of miR-7 was reduced in
GC cell lines (MGC-803, HGC-27, [69]). MiR-7 is known
as a tumor suppressor and can induce apoptosis in GC cell
lines via modulation of the PTEN/PI3K/AKT pathway [70].
It is worth noting that overexpression of ciRS-7 has not
straight effect on GC cell migration and proliferation but
since they can act miR-7 sponge, lead to intensifying
PTEN/PI3K/AKT pathway through repression of miR-7
[69].
The bladder cancer-related circular RNA-2 (BCRC-2),
also known as circHIPK3, expression level was explored
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Table 1 Selected circular RNAs in different cancers
Cancer Circular RNA Regulation of
the expression
in cancer
Genetic target (s) Effect (s) Model
used
Sample
type
Reference
GC CiRS-7 Up miR-7 Increase the overall survival In vitro Tissue,
cell line
Circ_104,916 Down Unknown Promote TNM and lymph node metastasis In vitro Tissue,
cell line
[36]
Circ_0000181 Down Unknown Lymphatic metastasis and distal metastasis In vitro Tissues,
plasma
[37]
BLC CircHIPK3 Down miR-558 Promote Vascular invasion and lymph node metastasis In vitro,
In vivo
Tissue,
Cell line
mice
[38]
CircTCF25 Up miR-103a
miR-107
CDK6
Promote cell proliferation,
Migration
In vitro Tissue,
Cell line
[39]
CircRNA BCRC4 Down miR-101 Association with cell apoptosis In vitro Tissue,
Cell line
[40]
ESCC Circ-ITCH Down miR-7 miR-17
miR-214
Inhibit the Wnt/β-catenin pathway In vitro,
In vivo
Tissue,
Cell line
[41]
hsa_circ_0067934 Up Unknown Promote the proliferation and migration In vitro Tissue,
cell line
[42]
circ-DLG 1 Up miR-515
miR-942
miR-589
miR-136
Promote the esophageal cell proliferation ability In vitro Tissue,
cell line,
Plasma
[43]
BC hsa_circ_0001982 Up miR-143 Promote the proliferation and invasion and suppress
apoptosis
In vitro Cell line,
Tissue
[44]
CircMYO9B Up miR-4316 Promote the BC cell proliferation, migration and
invasion, upregulation of FOXP4
In vitro,
In vivo
Tissue,
Cell line
[45]
hsa_circ_0007534 Up miR-593 Promote the BC cell proliferation, colony formation,
and invasion, upregulation of Mucin 19 (MUC19)
In vitro Tissue,
Cell line
[46]
CRC CircITGA7 Down miR-370-3p Promote the proliferation and metastasis in CRC cells
via Ras pathway
In vitro,
In vivo
Tissues,
cell line
[47]
hsa_circ_0000523 Down miR-31 Promote the proliferation and suppressed apoptosis
of CRC cells via indirectly regulating Wnt/β-catenin
signaling pathway
In vitro,
In vivo
Tissues,
cell line
[48]
Circ-001569 Up miR-145 Promote the proliferation, cell growth and invasion
of CRC
In vitro Tissues,
cell line
HCC CSMARCA5 Down miR-17-3p
miR-181b-5p
Promote the growth and metastasis of HCC In vitro,
In vivo
Tissues,
cell line
[49]
CircMTO1 Down miR-9 Promote the HCC progression and cell growth via
miR9-P21
In vitro,
In vivo
Tissues,
cell line
Circ_100,338 Up miR-141-3p Promote the lung metastasis, vascular invasion, and
TNM
In vitro,
In vivo
Tissues,
cell line
[50]
OSCC CircRNA_100290 Up miR-29b Suppress G1/S arrest, induce cell proliferation and
upregulate the expression of CDK6
In vitro,
In vivo
Tissues,
cell line
[51]
hsa_circ_0055538 Down p53/Bax/Apaf1/
caspase-3/
p21/Bcl2
Development of OSCC via the p53/Bcl-2/caspase
signaling pathway.
In vitro,
In vivo
Tissues,
Cell line
[52]
CircDOCK1 Up miR-196a-5p Inhibit the cell apoptosis via miR-196a-5p/BIRC3
pathway
In vitro,
In vivo
Tissues,
Cell line
[53]
PCa Circ-SMARCA5 Up Unknown Promote the cell cycle and inhibited cell apoptosis In vitro Cell line [54]
Circ-102,004 Up ERK/JNK/
Hedgehog
Promote the cell proliferation and decrease cell
apoptosis in PCa
In vitro,
In vivo
Tissues,
Cell line
[55]
CircMYLK Up MiR-29a Promote the PCa cell proliferation, invasion, and
migration
In vitro Tissue,
Cell line
[56]
Shabaninejad et al. Journal of Ovarian Research           (2019) 12:84 Page 4 of 12
in bladder tissue. On the basis of their result, it was
shown that circHIPK3 was markedly decreased in blad-
der cancer cell lines and tissues. Actually, the circHIPK3
suppressed the expression of heparanase (HPSE) through
sponging miR-558 [38]. HPSE is a vital mammalian en-
zyme that able to destroy heparin sulfate polymer and
has the ability in both the extracellular matrix and cell-
surface. This enzyme has a critical purpose in prelimin-
aries tumorigenesis, invasion, and angiogenesis many
cancers [71]. Due to circHIPK3 functions as a tumor
suppressor and miR-558 sponger in bladder cancer tis-
sue, reinforced expression of circHIPK3 could suppress
lymph node metastasis, angiogenesis, and vascular inva-
sion in bladder cancer cell line and inhibit bladder can-
cer metastasis and growth, in vivo [38].
In 2015, a study has surveyed the alteration in the ex-
pression level of circ-ITCH in esophageal squamous cell
carcinoma (ESCC) tissues. They have manifested that
circ-ITCH could act as a tumor suppressor in ESCC and
an increase in circ-ITCH expression ITCH leaded to
represses the Wnt/β-catenin pathway through the de-
struction of phosphorylated Dvl2 via sponge of miR-7,
miR-17 and miR-214. Their results also revealed an as-
sociation between circRNAs, mRNAs, and protein and
were proved that aberrant alteration among them may
cause cancer beginning and progression. They have an-
nounced the down-regulation expression of cir-ITCH in
ESCC tissue compare with matched normal tissue. Sub-
sequently, the level of ITCH positively with circ-ITCH
reduced and the expression of oncogenes including miR-
7, miR-17 and miR-214 overexpressed in ESCC and the
Wnt/β-catenin pathway not be repressed [41].
A significant overexpression of circMYO9B was re-
ported in breast cancer (BC) tissue. Specific siRNA
against circMYO9B caused suppression in proliferation,
invasion and migration in MCF7 and MDA-231 cell
lines. Likewise, the in vivo assay had shown a decrease
in level circMYO9B tumor growth. They also described
the mechanism of circMYO9B that sponged miR-4316
and enhanced expression of FOXP4 which act as tumor
suppressors and oncogene, respectively [72, 73]. Clearly,
the expression of miR-4316 was negatively related to cir-
cMYO9B and FOXP4 in BC tissues. Finally, they intro-
duced circMYO9B as a prognostic biomarker for the BC
patients and announced that CircMYO9B/miR-4316/
FOXP4 axis performed a crucial purpose in BC patho-
genesis [45].
Another group of scientists had reported a novel cir-
cRNA named circITGA7 which was markedly downreg-
ulated in colorectal cancer CRC) tissue and cell lines.
They also found that the linear form of ITGA7 has been
downregulated in this cancer. The downregulation of
circITGA7 and ITGA7 were associated with CRC pro-
gression. To the examine circITGA7 and ITGA7 roles in
CRC, ectopic circITGA7 were overexpressed and ob-
served proliferation and metastasis repression in CRC
cells, in vitro and in vivo. CircITGA7 could sponge miR-
370-3p and indirectly leaded to an increase in neurofi-
bromin 1 (NF1) which is its target and a negative regula-
tor of Ras pathway. On the other hand, CircITGA7
through suppressing RREB1, a transcription factor which
activate Ras pathway transcription factor, leaded to
ITGA7 overexpression. RNA-Seq and KEGG pathway
analysis showed that ITGA7 may be concomitant in
cytokine-related signaling pathways [47].
It is well-known that the miR-17-3p and miR-181b-5p
overexpression are contribute to the progression of hepa-
tocellular carcinoma (HCC) [74, 75]. Yu et al. have shown
that a circRNA named cSMARCA5, might regulate ex-
pression of miR-17-3p and miR-181b-5p oncomirs. But,
Table 1 Selected circular RNAs in different cancers (Continued)
Cancer Circular RNA Regulation of
the expression
in cancer
Genetic target (s) Effect (s) Model
used
Sample
type
Reference
LC Circ_100876 Up Unknown Promote the lymph node metastasis/TNM and overall
survival
In vitro Tissues [57]
CircFARSA Up miR-330-5p
miR-326
FASN
Promote the cell migration and invasion In vitro,
In silico
Tissue,
Plasma
[58]
CircRNF13 Down miR-93-5p Inhibit the cell invasion and metastasis In vitro Tissues,
Cell line
[59]
OS hsa_circ_0001564 Up miR-29c-3p Promote the proliferation activity, repressed cell cycle
arrest in G0/G1 phase, and suppressed apoptosis
In vitro Tissues,
Cell line
[60]
circ-0016347 Up miR-214 Promote the proliferation, invasion and metastasis In vitro,
In vivo
Tissues,
Cell line
[61]
circUBAP2 Up miR-143 Promote the osteosarcoma growth and inhibit the
apoptosis, and promote the osteosarcoma progression
In vitro,
In vivo
Tissues,
Cell line
[62]
BC Breast Cancer, BLC Bladder cancer, CRC Colorectal Cancer, GC Gastric Cancer, ESCC Esophageal squamous cell carcinoma, LC Lung Cancer, OSCC Oral squamous
cell carcinoma, HCC Hepatocellular carcinoma, OS Osteosarcoma, PCa Prostate cancer, TNM tumor-node-metastasis, EMT epithelial-mesenchymal transition
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they also have identified that cSMARCA5 is downregu-
lated in HCC tissue and cells while mRNA and protein
form of cSMARCA5 that is SMARCA5 were overex-
pressed. It has been noted that cSMARCA5 via sponging
miR-17-3p and miR-181b-5p can promote expression of a
tumor suppressor called TIMP3. Likewise, they deter-
mined that the downregulation of cSMARCA5 is an asso-
ciation of a tumor-promoter gene DHX9 in HCC. On the
basis of results, it is concluded that cSMARCA5 may pre-
vent the growth and metastasis of HCC and work as a
prognostic biomarker in HCC patients [49].
One report described the expression and function of
Circular SMARCA5 (circ-SMARCA5) in prostate cancer
(PCa). Due to circ-SMARCA5 up-regulation in PCa tis-
sues and cell lines, it is known as oncogenic circRNAs in
this cancer. The double hydrogen testosterone (DHT), is
a natural hormone and can be used as a medication,
treatment resulted in circ-SMARCA5 down-regulation
which can be concluded that it is an androgen-inducible
circRNA. The circ-SMARCA5 silencing in DU145, a
PCa originated cell line, inhibited cell cycle, cell prolifer-
ation and motivated apoptosis in PCa cells [54].
The circFARSA, derived from phenylalanyl-tRNA
synthetase alpha chain (FARSA) gene, has been upregu-
lated in non-small cell lung cancer (NSCLC) tissue
compared to non-cancerous tissue. The circFARSA over-
expression leaded to migration and invasion NSCLC cells.
In silico analysis and HITS-CLIP experiment showed that
miR-330-5p and miR-326 counterparted in the fatty acid
synthesis and they were introduced as circFARSA direct
targets. It is the hypothesis that circFARSA act as the spon-
ger for miR-330-5p and miR-326 and subsequently when
overexpressed lead to upregulation of FASN, a target of
both miRNAs [57].
CircNOL10 can be described as a round RNA whose ex-
pression takes place in low amounts when experiencing
lung cancer, although there is no clear information on the
functioning mechanisms in this disease [45]. Nan and col-
leagues evaluated the role and molecular processes of cir-
cNOL10 in their study of lung cancer advancement in the
laboratory conditions as well as in living tissues [45]. Ac-
cording to their findings, circNOL10 could considerably
hamper progress of lung cancer, while regulation of its ex-
pression was concurrent with methylation of its parental
gene named Pre-NOL10 as well as intertwining factor of
epithelial splicing regulatory protein 1 or ESRP1.
CircNOL10 elevates the expression of the transcribing
factor of sex comb on midleg-like 1 (SCML1) through
inhibition of ubiquitination, which subsequently influ-
ences the balance of HN polypeptide group through
SCML1. Moreover, circNOL10 can influence the per-
formance of mitochondria by regulation of the HN poly-
peptide group along with its effects on several signaling
routes, which will eventually hamper multiplication of
the cell along with the development of its cycle. As a re-
sult, apoptosis is promoted in the lung cancer cells and
results in the inhibition of their growth.
The present research aimed to find out how cir-
cNOL10 acts and what molecular mechanisms are in-
volved in advancement of lung cancer in addition to
indicating its engagement in the transcriptional regula-
tion of the HN polypeptide group via SCML1. According
to the findings, HN could hamper the development of
lung cancer cells. The information obtained through this
study may be helpful in identification of new molecular
treatments for lung cancer [45].
In oral squamous cell carcinomas (OSCC), circRNA_
100290 was significantly upregulated in tissue compared
with adjacent non-cancerous tissue. Actually, it was repre-
sented that circRNA_100290 regulate CDK6 expression
with the competing endogenous RNA (ceRNA) mechan-
ism. CircRNA_100290 could act as spongers for miR-29
family such as miR-29a, miR-29b, and miR-29c. Among
them, it was clarified that CDK6 is a direct target of miR-
29b. On the basis of considerations, it was exposed to cir-
cRNA_100290 and CDK6 were up-regulated in OSCC. To
investigate the circRNA_100290 function in OSCC cell
lines, the CDK6 expression was downregulated and caused
cell proliferation in vitro and in vivo with knocking down
of this circRNA [51].
The last circular RNA that introduced in this part is
circ_001564. The circ_001564 was highly upregulated in
osteosarcoma tissue and cell lines. In order to represent
the circ_001564 mechanisms, it was knocked down in
osteosarcoma cell lines (HOS and MG-63). The results
manifested restraining the cell proliferation, induced cell
cycle arrest in G0/G1 phase and increased apoptosis in
osteosarcoma cell lines. Base on bioinformatics analysis,
miR-29c-3p might be bonded to circ_001564 complemen-
tary; consequently, the oncogenic effect of hsa_circ_001564
was be reversed. In addition, the circ_001564 had function
as miR-29c-3p sponge that proposed competing endogen-
ous RNAs (ceRNAs) mechanisms in osteosarcoma [60].
CircRNAs in exosomes
For the first time, Huang et al., considered the existence of
circRNAs in exosomes [55]. As a result of this finding new
horizons were provided to examine circRNAs. In total, lo-
cating circRNAs in the cytoplasm can be done more con-
veniently, while different sorts of circRNAs can be found
in exosomes of various kinds of cytoplasm, which in turn
indicates the potential active regulation of special cir-
cRNAs transfer to exosomes through a selection-based
procedure. Nevertheless, there is no clear information
available on the mechanisms through which transfer of
circRNAs into exosomes takes place.
Two presumptions can be considered regarding how
circRNAs act in exosomes. According to the first one,
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they facilitate cell correspondence through the existing
substance in exosomes, making distal cells’ material and
transmission of information possible. Based on the sec-
ond assumption, circRNAs in exosomes assist in elimin-
ation of circRNAs collected in cells. However, recent
studies do not provide clear information on these pre-
sumptions. Lasda et al. endeavored to examine this as-
sumption and they accordingly hypothesized that
circRNAs in exosomes along with extracellular vesicles
could play the role of a mechanism removing endogen-
ous circRNAs [56].
Analysis of the corresponding number of circRNAs
along with linear RNAs was performed in the present
study taking extracellular vesicles (consisting of exosomes)
of the Hela, 293 t, U2OS cells into account. According to
the findings circRNAs outperformed the linear RNAs. Ac-
cordingly, it was stated that cells would probably have the
potential to manage circRNAs by their excretion through
extracellular vesicles. Since, it would be possible fot the
EVs to be captured by other cells, such as macrophages,
their function as message carriers could be possible in
order to maintain intercellular communication. This is a
new presumption which of course needs to be validated.
Enrichment of circRNAs was performed in another
study in platelet due to exonuclease [58]. But the question
was whether similar causes and findings could be found
when linear RNA was broken down. Consequently, this
potential issue was not thoroughly disapproved in the
present paper. Down-regulation of circRNAs takes place
in the colon of mutant KRAS, while its secretion could be
accomplished in the exosomes [59].
Three types of colorectal cancer cell lines were
investigated in the present research, including DLD-
1(wild-type along with G13D abnormal KRAS alleles),
DKO-1 (just abnormal KRAS allele) as well as DKs-8
(just wild-type KRAS allele). The circRNAs of the three
mentioned cell types underwent analysis through RNA-
Seq. Considerable down-regulation of circRNAs was
observed in DLD-1 as well as DKO-1 cells rather than
DKs-8 cells.
Later, examination of two other colorectal cancer cell
lines including HCT116 (abnormal KRAS allele) and
HKe3 (the kind of wild KRAS allele) went on, with the
findings obtained from sequencing confirming the fact
that overall expression of circRNAs was higher in HKe3
compared with HCT116. CircRNAs associated with
colorectal cancer is found in exosomes and considerable
down-regulation of circFAT1 was observed contrary to
up-regulation of circRTN4. However, there were no evi-
dent changes in the respective linear mRNA which was
under regulating effects of these genes as it was evident
in circRNAs. Moreover, it could be stated that transmis-
sion of cirRNAs into exosomes would be performed
through an elective procedure [59].
Circular RNAs and ovarian cancer
Accumulating studies have confirmed interplay between
circRNAs and human disorders including embryonic de-
velopment, Alzheimer’s disease, diabetes and also can-
cers [15, 76]. Ovarian cancer is one of the major
prevalent and causing cancer mortality in female [77].
Dysregulation of signaling pathways and cellular mecha-
nisms have crucial role in cancer initiation, progression
and invasion [69, 78]. Regarding regulatory roles of cir-
cRNAs and ovarian cancer impotency, the correlation
and relation between them are attractive for researchers.
In recent years, numerous studies focused on differen-
tially expressed circRNAs and their function in ovarian
cancers, suggesting circRNAs as potentially novel bio-
markers or therapeutic agents in this disease (Table 2).
For the first time, Ahmed, et al., performed a robust cir-
cRNAs expression analysis in clinical ovarian tumors.
They reported that abundant number of circRNAs differ-
entially expressed in tumor samples. They also examined
differential mRNA and circRNA expression signatures be-
tween primary and metastasis ovarian tumor. Regarding
the RNA exonuclease resistance and stability of circRNAs
[92], they distinguished suitably the primary tumor from
metastatic lesion rather mRNAs. Interestingly, signaling
pathways such as STAT, AKT, NF-kB, TGF-B, ILK and
HGF and VEGF that are typically activated for linear RNA
producing and angiogenesis are downregulated for cir-
cRNA in ovarian metastasis cancer [93]. Also, miR-24 and
Let-7, well-known tumor suppressor miRNAs [94, 95],
expressed in low level in primary tumor. The high
expressed candidate circRNAs encompass several binding
sites, suggesting the possible sponge roles of them for both
miRNAs. Over all, the circRNAs/ miRNAs/ mRNAs cross
talk indicated potentially role of circRNAs as tumor acti-
vator of inhibitor [93].
The circ-CSPP1 or circ-0001806 is derived from centro-
some/spindle pole-associated protein 1 (CSPP1) gene
which is located in 8q13.2 region of human genome. The
oncogenic function of CSPP1 have determined in luminal
breast cancer and B-cell lymphoma [96, 97]. Also, the ex-
pression level of circ-CSPP1 was performed in border line,
benign, ovarian tumor tissues, and non-tumor tissues. The
circ-CSPP1 expressed remarkably high in borderline and
tumor tissues rather benign and cancer tissues. Consist-
ently, this circRNA expression was correlated with stage
II-VI. Subsequent knocking down of circ-CSPP1 caused
an arrest in cell growth, invasion and migration and in-
versely, the overexpression stimulated cancer properties.
A negative correlation between miR-1236-3p and circ-
CSPP1 was observed in ovarian cell lines. Dual luciferase
assay revealed that circ-CSSP1 acted as miR-1236-3p
decoy [84]. Reportedly, miR-1236-3p suppressed tumor
development through targeting zinc finger E-box binding
homobox 1 (ZEB1) in ovarian cancer [98]. Thus, circ-
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CSPP1 sponged miR-1236-3p and attenuated its silen-
cing effect on ZEB1, consequently stimulated EMT
and cancer development. Moreover, the expression of
vascular endothelial growth factor A (VEGFA) and
matrix metalloproteinase-2 (MMP2), which are onco-
genic proteins, decreased significantly in silenced circ-
CSPP1 cell line [84].
The overexpression of circRNA-000479, or circEPSTI1
was reported in triple-negative breast (TNBC) cancer tis-
sues. The high level of circEPSTI1 was correlated with
reduced survival in these patients. The circEPSTI1 pro-
moted proliferation and clonal formation and suppressed
apoptosis in TNBC cell lines. Moreover, xenograft and
invitro experiments confirmed its role as a decoy of miR-
4753 and miR-6809 to modulate BCLI 1A [99]. The cir-
cEPSTI1 also played an important role in ovarian cancer
regulation. Compared to adjacent non-tumor tissue, the
circEPST1 was overexpressed in 50 paired ovarian cancer
sample. Also, the circEPSTI1 silencing impaired cell
growth, invasion but induced apoptosis. Knocking down
of circEPSTI1 leaded to a decrease in ovarian tumor size
and lung metastasis in mouse xenograft which indicated
the circEPSTI1 role in ovarian cancer progression and me-
tastasis invivo. Based on experimental assays, this circRNA
mostly localized in cytoplasm was capable to sponge miR-
942, which was down regulated in ovarian cancer tissues.
EPSTI1, linear form of circEPSTI1, also overexpressed in
ovarian cancer tissues. Luciferase assay showed that miR-
942 directly targeted EPSTI1, indicating the circEPSTI1
effect on EPSTI1 [83].
The role of circHIPK3 was investigated in some hu-
man malignancies. For instance, the circHIPK3 overex-
pression was reported in prostate cancer tissues which
was correlated with tumor stage. This circRNA relieved
MCL1 expression by sponge miR-193-3p [100]. Its ex-
pression level and function was tested and the data re-
vealed upregulation of circHIPK3 in lung cancer cells
compared with lung epithelial cells. It could promote
oncogenic properties by acting as a decoy for miR-124
and subsequently causing upregulation in its target in-
cluding SphK1, CDK4 and STAT3 [101]. This circRNA
could sponge multiple miRNAs including miR-124, miR-
584, miR-29a, miR-29b, miR-379 and miR-558 [38, 102].
Also, it was investigated the circHIPK3 expression cor-
relation with clinicopathological factors in the tissues as-
sociated with ovarian cancer.
The circHIPK3 profiling revealed an increased expres-
sion in tumor samples. The over expressed cases suf-
fered from node invasion and inappropriate prognosis
[85]. Contradictory, it has been reported that circHIPK3
expressed in low level in epithelial ovarian cancer, but it
was highly expressed in IOSE80 cell, a normal ovarian
tissue cell line. In addition, the authors claimed that
knocking down of circHIPK3 induced cell growth,
migration and metastasis and repressed apoptosis of
ovarian cancer cells [86]. The circ-0051240 is another
circRNA that play a crucial role in ovarian cancer. The
over expression of circ-0051240 in ovarian cancer tissues
enhanced tumor formation, cell growth, progression and
invasion, invivo and invitro. It was identified that the
circ-0051240 affected via tapping miR-637 which post-
transitionally inhibited Kallikrein 4 (KLK4) expression
[88]. It was reported that the KLK4 overexpression was
related with more aggressive and poor-prognostic ovar-
ian cancer [103].
Emerging evidence represented the over expression
and oncogenic role of miR-10a in ovarian cancer
[104, 105]. Luo and colleagues indicated a reduction
in circ-ITCH expression in cancerous ovarian cell
lines in comparison with non-cancerous ones and its
effect on miR-10a level. The over expression of circ-
ITCH promoted apoptosis and inhibited cell prolifera-
tion in ovarian cancer cells. The miR-10a expression
was adversely regulated with circ-ITCH and the
miRNA overexpression compensated the circ-ITCH
inhibition effects on cell growth. Interestingly, the
circ-ITCH expression was independent with miR-10a
expression [89]. The circ-LARP4 is another down reg-
ulated circRNA in ovarian cancer tissue. The low ex-
pression of circ-LARP4 was considerably associated
with lymph node invasion and also poor prognosis.
Hence, it might be used as a potentially novel bio-
marker for ovarian cancer detection [90].
Conclusion
Previously, circRNAs were known as errors during RNA
splicing. Developing technology in recent years im-
proved our knowledge about this class of lncRNAs.
Nowadays, they are understood to be a frequently stable
RNA molecule which expressed in various tissues and
cells. The circRNAs represent a miRNAs decoy role to
indirectly modulate their target genes. Accumulating evi-
dences revealed the critical regulatory roles of them in
tumorigenesis, with cancer-type specific distinguishable
expression levels. CircRNAs biological functions, such as
interactions with specific mRNA, protein and specifically
miRNAs provide a regulatory network for cancer pro-
gression and invasion, so promise to providing more re-
liable, sensitive diagnoses and more effective cancer
therapy. Based on reports, ovarian cancer is the sixth
and one of the lethality cancer type in women world-
wide. Without doubt, accurate knowledge about regulat-
ing molecular mechanisms, including circRNAs role
provides a promising opportunity to better understand-
ing of ovarian cancer. Subsequently novel approaches
can be identified to early diagnosis, prognosis, follow up
and therapeutics of ovarian cancers.
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